Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDO1 is a new biomarker to discriminate aggressive forms of prostate cancer.

Oncogene·2026
Same author

Impact of heme on the therapeutic efficacy of anti-CD20 antibodies.

The Journal of biological chemistry·2026
Same author

Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues.

Nature immunology·2026
Same author

Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues.

Nature immunology·2025
Same author

DC subsets and states unraveled across human juxtatumoral and malignant tissues.

Nature immunology·2025
Same author

[Protect always and everywhere scientific research against obscurantism].

Medecine sciences : M/S·2025

Related Experiment Video

Updated: Dec 11, 2025

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

2.4K

[Antibodies: better knowledge for a better use].

Riad Abès1, Charles-Antoine Dutertre, Jean-Luc Teillaud

  • 1Laboratoire français du fractionnement et des biotechnologies, Les Ulis, France. Inserm U872, Paris, F-75006 France.

Medecine Sciences : M/S
|December 29, 2009
PubMed
Summary
This summary is machine-generated.

Monoclonal antibody therapy is expanding, but challenges remain in improving efficacy and reducing adverse events. Future research focuses on antibody engineering and target selection for enhanced therapeutic outcomes.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.4K
Printed Glycan Array: A Sensitive Technique for the Analysis of the Repertoire of Circulating Anti-carbohydrate Antibodies in Small Animals
08:49

Printed Glycan Array: A Sensitive Technique for the Analysis of the Repertoire of Circulating Anti-carbohydrate Antibodies in Small Animals

Published on: February 14, 2019

7.2K

Related Experiment Videos

Last Updated: Dec 11, 2025

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

2.4K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.4K
Printed Glycan Array: A Sensitive Technique for the Analysis of the Repertoire of Circulating Anti-carbohydrate Antibodies in Small Animals
08:49

Printed Glycan Array: A Sensitive Technique for the Analysis of the Repertoire of Circulating Anti-carbohydrate Antibodies in Small Animals

Published on: February 14, 2019

7.2K

Area of Science:

  • Immunology and protein engineering.
  • Focus on immunoglobulin G1 (IgG1) structure and function.

Context:

  • Therapeutic monoclonal antibody use is rapidly increasing.
  • Significant advancements in understanding antibody structure, especially IgG1.
  • Existing clinical applications face challenges in efficacy and safety.

Purpose:

  • To address key challenges in monoclonal antibody therapy.
  • To explore strategies for enhancing antibody efficacy and safety.
  • To improve the reliability of preclinical models for human extrapolation.

Summary:

  • Despite progress in understanding antibody structure, challenges persist in maximizing therapeutic efficacy and minimizing adverse clinical events.
  • Selecting appropriate target antigens is crucial for effective treatment outcomes.
  • Antibody molecular plasticity and advanced engineering approaches offer promising avenues for future drug development.

Impact:

  • Advances in antibody engineering and target identification are crucial for developing more effective and safer antibody-based therapeutics.
  • Future research aims to overcome current limitations, positioning monoclonal antibodies as vital drugs for human health.
  • Improved preclinical models are needed for reliable translation of antibody therapies to clinical practice.